PT2367561E - Composições e métodos para o tratamento da doença celíaca - Google Patents

Composições e métodos para o tratamento da doença celíaca Download PDF

Info

Publication number
PT2367561E
PT2367561E PT98284532T PT09828453T PT2367561E PT 2367561 E PT2367561 E PT 2367561E PT 98284532 T PT98284532 T PT 98284532T PT 09828453 T PT09828453 T PT 09828453T PT 2367561 E PT2367561 E PT 2367561E
Authority
PT
Portugal
Prior art keywords
compositions
treatment
methods
celiac disease
celiac
Prior art date
Application number
PT98284532T
Other languages
English (en)
Portuguese (pt)
Inventor
Robert Paul Anderson
Jessica Anne Stewart
James Anthony Dromey
Jason Allan Tye-Din
Original Assignee
Immusant Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immusant Inc filed Critical Immusant Inc
Publication of PT2367561E publication Critical patent/PT2367561E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
PT98284532T 2008-11-30 2009-11-30 Composições e métodos para o tratamento da doença celíaca PT2367561E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11864308P 2008-11-30 2008-11-30

Publications (1)

Publication Number Publication Date
PT2367561E true PT2367561E (pt) 2015-10-23

Family

ID=42225141

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98284532T PT2367561E (pt) 2008-11-30 2009-11-30 Composições e métodos para o tratamento da doença celíaca

Country Status (16)

Country Link
US (5) US8835603B2 (enExample)
EP (3) EP2977053B1 (enExample)
JP (2) JP5851243B2 (enExample)
CN (2) CN105079781B (enExample)
AU (1) AU2009321481B2 (enExample)
BR (1) BRPI0922122A2 (enExample)
CA (2) CA2744787C (enExample)
DK (2) DK2367561T3 (enExample)
ES (2) ES2549481T3 (enExample)
HK (1) HK1249446A1 (enExample)
HR (1) HRP20150873T1 (enExample)
HU (1) HUE027237T2 (enExample)
MX (1) MX346450B (enExample)
NZ (1) NZ593474A (enExample)
PT (1) PT2367561E (enExample)
WO (1) WO2010060155A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212885D0 (en) 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
US10105437B2 (en) 2004-04-28 2018-10-23 Btg International Limited Epitopes related to coeliac disease
EP1755639B1 (en) 2004-04-28 2017-08-16 BTG International Limited Epitopes related to coeliac disease
WO2010060155A1 (en) 2008-11-30 2010-06-03 Nexpep Pty Ltd Compositions and methods for treatment of celiac disease
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CN108117586A (zh) 2010-08-10 2018-06-05 洛桑聚合联合学院 红细胞结合性治疗剂
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
RU2017137415A (ru) * 2011-01-20 2019-02-11 Иммьюносайнсиз Лаб, Инк. Способы и устройство для обнаружения глютеновой чувствительности и ее дифференцирования с целиакией
ITRM20110487A1 (it) * 2011-09-19 2013-03-20 Consiglio Per La Ricerca E La Speri Mentazione In Peptidi aventi effetto protettivo nei confronti della attività infiammatoria del peptide 31-43 della a-gliadina nella malattia celiaca.
ES2402286B1 (es) * 2011-09-29 2014-03-04 Universidad De Valladolid Péptido inmunogénico del gluten y sus aplicaciones.
EP2812344A4 (en) 2012-02-07 2015-10-28 Vibrant Holdings Llc SUBSTRATES, PEPTIDE NETWORKS AND METHODS
KR20210096312A (ko) 2012-06-21 2021-08-04 노쓰웨스턴유니버시티 펩티드 접합된 입자
US10006909B2 (en) 2012-09-28 2018-06-26 Vibrant Holdings, Llc Methods, systems, and arrays for biomolecular analysis
US10286376B2 (en) 2012-11-14 2019-05-14 Vibrant Holdings, Llc Substrates, systems, and methods for array synthesis and biomolecular analysis
EP2928500B1 (en) 2012-12-04 2019-03-06 Phosphorex Inc. Microparticles and nanoparticles having negative surface charges
CN105263476A (zh) 2013-03-13 2016-01-20 库尔制药开发公司 用于治疗炎症的免疫修饰性颗粒
WO2014152233A1 (en) * 2013-03-14 2014-09-25 Immusant, Inc. Placebo-controlled gluten challenge method
WO2014182897A2 (en) * 2013-05-08 2014-11-13 Jm Biologicals Compositions and methods for the production of gluten free food products
IL318076A (en) 2013-08-13 2025-02-01 Univ Northwestern Peptide-conjugated particles
CA2923822A1 (en) 2013-09-10 2015-03-19 Immusant, Inc. Dosage of a gluten peptide composition
US20160238590A1 (en) * 2013-09-20 2016-08-18 Immusant, Inc. Compositions and methods related to oat sensitivity
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
EA201691686A1 (ru) 2014-02-21 2017-03-31 Эколь Политекник Федераль Де Лозан (Эпфл) Терапевтические средства с углевод-опосредованной адресной доставкой
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
EP3134730A4 (en) * 2014-04-24 2018-01-17 Immusant Inc. Methods for diagnosing celiac disease using circulating cytokines/chemokines
US10900964B2 (en) 2014-09-10 2021-01-26 Vibrant Holdings, Llc Peptide microarrays and novel biomarkers for celiac disease
US10370718B2 (en) 2014-09-29 2019-08-06 Immusant, Inc. Use of HLA genetic status to assess or select treatment of celiac disease
AU2015349728A1 (en) 2014-11-21 2017-07-13 Immusant, Inc. Peptides for use in treatment and diagnosis of type 1 diabetes
KR101736744B1 (ko) 2014-12-03 2017-05-17 주식회사 한국유전자정보연구원 셀리악병 진단용 프라이머 세트와 이를 이용한 셀리악병 진단방법
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US20180250359A1 (en) * 2015-08-30 2018-09-06 Diamyd Medical Ab Combination therapy using gliadin and gamma aminobutyric acid
JP7194593B2 (ja) 2015-12-23 2022-12-22 クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド 共有ポリマー抗原コンジュゲート化粒子
WO2017143346A1 (en) 2016-02-18 2017-08-24 Cour Pharmaceuticals Development Company, Inc. Process for the preparation of tolerizing immune-modulating particles
EP3464322B1 (en) * 2016-06-05 2023-04-05 Tel HaShomer Medical Research Infrastructure and Services Ltd. Novel molecules for the treatment of inflammation
EP3474881A1 (en) 2016-06-28 2019-05-01 Immusant, Inc. Escalating dosage schedules for treating celiac disease
BR112019014418A2 (pt) * 2017-01-12 2020-04-14 Probi Ab composições probióticas e usos das mesmas
US10538808B2 (en) 2017-05-26 2020-01-21 Vibrant Holdings, Llc Photoactive compounds and methods for biomolecule detection and sequencing
WO2018232176A1 (en) 2017-06-16 2018-12-20 The University Of Chicago Compositions and methods for inducing immune tolerance
CA3074839A1 (en) 2017-09-07 2019-03-14 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof
AU2018357840A1 (en) * 2017-10-30 2020-05-14 Immusant, Inc. Dosing regimens for celiac disease
JP6568193B2 (ja) 2017-12-19 2019-08-28 ホーユー株式会社 エピトープ
AU2019216747B2 (en) * 2018-02-08 2025-01-23 Cour Pharmaceuticals Development Company Inc. Treatment of Celiac Disease with tolerizing particles
EP3790985A4 (en) 2018-05-09 2022-02-16 Vibrant Holdings, LLC METHOD OF SYNTHESIS OF A POLYNUCLEOTIDARRAY USING PHOTOACTIVATED AGENTS
EA202092723A1 (ru) 2018-05-09 2021-04-09 Зе Юниверсити Оф Чикаго Композиции и способы, касающиеся иммунной толерантности
EP3882261A4 (en) * 2018-10-31 2023-02-08 Ajinomoto Co., Inc. COMPOUND COMPRISING A SUBSTANCE HAVING AN AFFINITY FOR AN ANTIBODY, CLEAVAGE SITE AND CORRESPONDING REACTIVE GROUP OR SALT
WO2020181272A1 (en) * 2019-03-06 2020-09-10 Cue Biopharma, Inc. Antigen-presenting polypeptides with chemical conjugation sites and methods of use thereof
CN114302741A (zh) * 2019-07-19 2022-04-08 密执安大学评议会 用于治疗自身免疫性疾患的组合物和方法
JP7374687B2 (ja) * 2019-09-26 2023-11-07 三和酒類株式会社 ペンタペプチド化合物
WO2021102182A1 (en) * 2019-11-19 2021-05-27 Spark Therapeutics, Inc. Secretable protein induced immune tolerization and treatment of autoimmune, allergic and other diseases and disorders
MX2023012257A (es) 2021-04-16 2024-01-08 Cour Pharmaceuticals Dev Company Inc Método de rastreo del mantenimiento de la inmunotolerancia.
KR20250052378A (ko) 2022-07-21 2025-04-18 안티바 바이오사이언시즈, 인크. Hpv 감염 및 hpv-유도 신생물의 치료를 위한 조성물 및 투여 형태
WO2024168151A2 (en) * 2023-02-09 2024-08-15 The Board Of Trustees Of The Leland Stanford Junior University Capped peptides and methods for using the same

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4740371A (en) 1984-09-17 1988-04-26 International Institute Of Cellular And Molecular Pathology Treatment of allergy
DE3779909T2 (de) 1986-03-06 1993-01-07 Commw Scient Ind Res Org In-vitro-testverfahren zum nachweis zellulaerer immunresponsen.
FR2615622B1 (fr) 1987-05-19 1994-05-06 Ire Medgenix Sa Dosage plasmatique de monokines
US5547669A (en) 1989-11-03 1996-08-20 Immulogic Pharma Corp Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I
US5998366A (en) 1990-09-21 1999-12-07 The Regents Of The University Of California Method for ameliorating glutamic acid decarboxylase associated autoimmune disorders
US5674978A (en) 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
IL105153A (en) 1992-03-25 1999-12-22 Immulogic Pharma Corp Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
JPH10511541A (ja) 1994-08-26 1998-11-10 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア Ｔ細胞応答を調節するための方法および組成物
US6759234B1 (en) 1994-09-02 2004-07-06 Immulogic Pharmaceutical Corporation Compositions and methods for administering to humans, peptides capable of down regulating an antigen specific immune response
JPH10505356A (ja) 1994-09-02 1998-05-26 イミユロジク・フアーマシユーチカル・コーポレーシヨン ヒトへの投与のための組成物および方法、抗原特異的免疫応答のダウンレギュレーションを行うことが可能なペプチド
US5750356A (en) 1996-05-31 1998-05-12 Anergen, Inc. Method for monitoring T cell reactivity
EP0905518A1 (en) 1997-09-23 1999-03-31 Academisch Ziekenhuis Leiden Peptides specific for gluten-sensitive T-cells and use thereof
US6300308B1 (en) 1997-12-31 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions for inducing autoimmunity in the treatment of cancers
GB9923306D0 (en) 1999-10-01 1999-12-08 Isis Innovation Diagnostic and therapeutic epitope, and transgenic plant
US6667160B2 (en) 2000-03-15 2003-12-23 Kenneth D. Fine Method for diagnosing immunologic food sensitivity
US8110218B2 (en) 2000-11-30 2012-02-07 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein-lipid complexes
EP1241476A1 (en) 2001-03-12 2002-09-18 Mabtech AB Diagnosis of metal allergy through cytokine release by T-cells in vitro
US7094555B2 (en) 2001-04-05 2006-08-22 Benaroya Research Institute At Virginia Mason Methods of MHC class II epitope mapping, detection of autoimmune T cells and antigens, and autoimmune treatment
MXPA03009313A (es) 2001-04-12 2004-11-12 Academish Ziekenhuis Leiden Metodos y medios para uso de receptores de celulas t restringidos por hla-dq y peptidos derivados de prolamina unidos a hla-dq.
FI20010868A0 (fi) 2001-04-25 2001-04-25 Markku Maeki Menetelmä ja välineet gluteenin indusoimien tautien havaitsemiseksi
ATE414534T1 (de) 2001-12-05 2008-12-15 Circassia Ltd Immunotherapeutische methoden und systeme
EP1332760A1 (en) 2002-02-04 2003-08-06 Academisch Ziekenhuis Leiden Novel epitopes for celiac disease and autoimmune diseases, methods for detecting those and novel non-antigenic food compounds
EP2364718B1 (en) 2002-02-14 2016-07-06 The Board of Trustees of the Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US7320788B2 (en) 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
AU2003234597A1 (en) 2002-05-14 2003-12-02 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7202216B2 (en) 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7462688B2 (en) 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
GB0212885D0 (en) 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
AU2002952834A0 (en) 2002-09-16 2002-12-05 The Walter And Eliza Hall Institute Of Medical Research A method of treating an autoimmune disease
AU2002952548A0 (en) 2002-11-08 2002-11-21 Cellestis Limited Diagnostic assay
AU2003277989B2 (en) 2002-11-08 2010-04-22 QIAGEN Australia Holding Pty. Ltd. Diagnostic assay for measuring a cell mediated immune response
EP1563300B1 (en) 2002-11-20 2012-04-18 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic method for celiac sprue
US7563864B2 (en) * 2004-04-26 2009-07-21 Celiac Sprue Research Foundation Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
EP1755639B1 (en) * 2004-04-28 2017-08-16 BTG International Limited Epitopes related to coeliac disease
GB0409775D0 (en) 2004-04-30 2004-06-09 Mabtech Ab Assay
WO2006050138A2 (en) 2004-10-29 2006-05-11 Benaroya Research Institute At Virginia Mason Methods of generating antigen-specific cd4+cd25+ regulatory t cells, compositions and methods of use
WO2007022477A2 (en) 2005-08-17 2007-02-22 Multicell Immunotherapeutics, Inc. Methods and compositions to generate and control the effector profile of t cells
US20090304754A1 (en) 2005-10-12 2009-12-10 Srebrenka Robic Pegylated glutenase polypeptides
JP2009536157A (ja) 2006-04-13 2009-10-08 ペプチミューン，インコーポレイテッド エピトープ透過性の指向された拡張を介した指向性配列ポリマー組成物の設計方法および合成方法
ES2666658T3 (es) * 2007-01-25 2018-05-07 Intrexon Actobiotics Nv Tratamiento de enfermedad inmune mediante suministro a la mucosa de antígenos
ITFE20070003A1 (it) 2007-02-01 2007-05-03 Girolamo Calo' Utilizzo di peptidi ricchi in prolina e glutamina capaci di legarsi alle molecole hla-dq2 e dq8 come "carriers specifici" di agenti capaci di danneggiare o uccidere le cellule che esprimono dette molecole hla nel contesto dell a mucosa enterica di pa
AU2008229636B2 (en) 2007-03-16 2014-08-14 Qiagen Sciences Llc A cell-mediated immune response assay and kits therefor
AU2009239558B2 (en) 2008-04-21 2013-05-02 Bio-Rad Laboratories, Inc. Recombinant deamidated gliadin antigen
WO2009139887A2 (en) 2008-05-16 2009-11-19 The Board Of Trustees Of The Leland Stanford Junior University Non-inflammatory gluten peptide analogues as biomarkers for celiac sprue
WO2010009494A1 (en) 2008-07-25 2010-01-28 Cellestis Limited A diagnostic method
WO2010060155A1 (en) 2008-11-30 2010-06-03 Nexpep Pty Ltd Compositions and methods for treatment of celiac disease
WO2011000773A1 (en) 2009-07-02 2011-01-06 Dsm Ip Assets B.V. Testing efficacy for celiac disease
WO2011075773A1 (en) 2009-12-23 2011-06-30 Cellestis Limited An assay for measuring cell-mediated immunoresponsiveness
US10578612B2 (en) 2010-05-28 2020-03-03 Cellestis International Pty Ltd. Diagnostic assay
US20110311536A1 (en) 2010-06-11 2011-12-22 Dana-Farber Cancer Institute, Inc. Prevention of type 1 diabetes by treg vaccination with an insulin mimetope
CA2840484C (en) 2011-06-29 2020-04-14 Cellestis Limited A cell mediated immune response assay with enhanced sensitivity
WO2013016427A1 (en) 2011-07-25 2013-01-31 Alvine Pharmaceuticals, Inc. Methods and pharmaceutical compositions for treating celiac disease and gluten intolerance
WO2013036303A2 (en) 2011-09-06 2013-03-14 Selecta Biosciences, Inc. Induced tolerogenic dendritic cells to reduce systemic inflammatory cytokines
ES2402286B1 (es) 2011-09-29 2014-03-04 Universidad De Valladolid Péptido inmunogénico del gluten y sus aplicaciones.
CN106117330B (zh) 2011-12-05 2019-12-06 伯乐实验室公司 重组脱酰胺化麦醇溶蛋白抗原
WO2014152233A1 (en) 2013-03-14 2014-09-25 Immusant, Inc. Placebo-controlled gluten challenge method
CA2923822A1 (en) 2013-09-10 2015-03-19 Immusant, Inc. Dosage of a gluten peptide composition
US20160238590A1 (en) 2013-09-20 2016-08-18 Immusant, Inc. Compositions and methods related to oat sensitivity
EP3134730A4 (en) 2014-04-24 2018-01-17 Immusant Inc. Methods for diagnosing celiac disease using circulating cytokines/chemokines

Also Published As

Publication number Publication date
JP5851243B2 (ja) 2016-02-03
BRPI0922122A2 (pt) 2017-08-01
HK1162918A1 (en) 2012-09-07
EP2367561A1 (en) 2011-09-28
HUE027237T2 (en) 2016-10-28
DK2367561T3 (en) 2015-08-24
EP2367561A4 (en) 2012-06-06
HRP20150873T1 (hr) 2015-11-06
US20190048047A1 (en) 2019-02-14
CN102438643B (zh) 2015-07-01
CA2744787C (en) 2019-06-11
MX2011005632A (es) 2011-11-29
EP2977053A1 (en) 2016-01-27
JP2016128402A (ja) 2016-07-14
ES2549481T3 (es) 2015-10-28
JP2012510431A (ja) 2012-05-10
JP6027215B2 (ja) 2016-11-16
CN105079781A (zh) 2015-11-25
US8835603B2 (en) 2014-09-16
AU2009321481B2 (en) 2014-08-21
US20150050303A1 (en) 2015-02-19
EP2977053B1 (en) 2017-07-05
AU2009321481A1 (en) 2011-07-07
HK1249446A1 (en) 2018-11-02
US20170158743A1 (en) 2017-06-08
HK1219898A1 (en) 2017-04-21
EP3269379A1 (en) 2018-01-17
NZ593474A (en) 2013-04-26
CA2744787A1 (en) 2010-06-03
WO2010060155A1 (en) 2010-06-03
US9464120B2 (en) 2016-10-11
CA3042826A1 (en) 2010-06-03
MX346450B (es) 2017-03-17
CN102438643A (zh) 2012-05-02
US20110293644A1 (en) 2011-12-01
EP2367561B1 (en) 2015-05-20
US20210115096A1 (en) 2021-04-22
ES2642096T3 (es) 2017-11-15
CN105079781B (zh) 2018-07-20
DK2977053T3 (en) 2017-10-09

Similar Documents

Publication Publication Date Title
PT2367561E (pt) Composições e métodos para o tratamento da doença celíaca
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI0919238A2 (pt) métodos e composições para o tratamento de câncer
BRPI0921237A2 (pt) métodos e composições para o tratamento de distúrbios associados ao complemento
BR112012004979A2 (pt) composições para o tratamento de semente e métodos
BRPI0911757A2 (pt) composiÇÕes e mÉtodos para tratar distérbios digestivos.
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
HUE036780T2 (hu) Új kompozíciók és eljárások immunológiai vonatkozású betegségek kezelésére
BRPI1008566A2 (pt) métodos e composições para o diagnóstico e tratamento de câncer
BRPI0908854A2 (pt) composições e métodos para o tratamento de tumor de origem hematopoética
BRPI0911612A2 (pt) composições e métodos para o tratamento da esclerose múltipla.
PT2349132T (pt) Aparelho para tratamento da drge
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
BRPI0916862A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias
BRPI1007600A2 (pt) composições e métodos para tratamento de doenças cardiovasculares
HUE049880T2 (hu) Anyag és eljárások Her-3-mal összefüggõ betegségek kezelésére vagy megelõzésére
BRPI0918670A2 (pt) composições e métodos para o tratamento de disordens mediados por ige
BRPI1008564A2 (pt) métodos e composições para o dignóstico e tratamento de câncer
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
BRPI0822349A2 (pt) composições e métodos para tratar doenças lisossômicas
BRPI1011325A2 (pt) composições e métodos para o tratamento de inflamação
BRPI1007929A2 (pt) "métodos e composições para o tratamento de neovascularização".
EP2271352A4 (en) COMPOSITIONS AND METHODS FOR TREATING NEOPLASTIC DISEASE